H.I.G. Capital has acquired a majority stake in Navitas Life Sciences to accelerate CRO growth.
A technology-enabled specialty research organization, Navitas Life Sciences provides functional services and specialized technology such as pharmacovigilance technologies and life sciences data analytics for clients around the world. The company’s strong fundamentals combined with high growth potential made it an attractive acquisition opportunity for H.I.G. Capital, whose global network and diverse experience across healthcare and life sciences make them an ideal partner to support Navitas’ continued growth as a global next-generation CRO.
Crosstree helped H.I.G. confirm that Navitas was a good platform to be leveraged for additional growth capabilities through:
- Evaluating valuation and terms
- Facilitating strategic, operational, and financial diligence
- Developing and evaluating growth strategies and conducting feasibility and ROI analyses